CXCR1 and COVID-19: Targeting the IL-8/CXCR1/CXCR2 axis could allow the opportunity to not only identify new therapeutics for the treatment of COVID-19-related ARDS, but also to provide the new therapeutics to treat ARDS of any origin or cause with the aim to modulate the inflammatory response and its clinical consequences.